美国 · SEC FORM 4
Corvus Pharmaceuticals, Inc.
CRVS · Nasdaq · CIK 0001626971 · Healthcare · Biotechnology
内部人信号
2 位买方 · 3 条买入交易行 · $333.7K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ 角色得分低 · 买入者中职位最高的是：President and CEO（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 51.2
- 51.2
- 51.1
- 51.1
- 51.0
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -18.7%
- 3M
- -28.5%
- 6M
- -30.3%
- 12M
- +50.3%
波动率与流动性
- 波动率
- 140.2%
- Beta
- —
- 平均每日成交额
- USD 10.3M
估值
- 市值
- USD 885.0M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -25.0%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-06 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 17,797,751
- 上期报告
- 17,180,341
- 日均成交量
- 1,336,813
- 回补天数
- 13.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-11 | Moore David Scott | 买入 (P) | Common Stock | 21,700 | USD 11.53 | USD 250,201 | SEC 申报 ↗ |
| 2026-05-18 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 6,932 | USD 12.04 | USD 83,453 | SEC 申报 ↗ |
| 2024-05-06 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 577,634 | USD 1.73 | USD 999,307 | SEC 申报 ↗ |
| 2024-05-06 | Jones William Benton | 买入 (P) | Common Stock | 20,000 | USD 1.73 | USD 34,600 | SEC 申报 ↗ |
| 2023-05-15 | Grais Linda | 买入 (P) | Common Stock | 10,000 | USD 2.45 | USD 24,500 | SEC 申报 ↗ |
| 2022-12-20 | Jones William Benton | 买入 (P) | Common Stock | 20,000 | USD 0.79 | USD 15,800 | SEC 申报 ↗ |
| 2022-12-14 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 10,000 | USD 0.78 | USD 7,800 | SEC 申报 ↗ |
| 2022-12-14 | LEA LEIV | 买入 (P) | Common Stock | 4,000 | USD 0.84 | USD 3,360 | SEC 申报 ↗ |
| 2022-12-13 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 50,000 | USD 0.74 | USD 37,000 | SEC 申报 ↗ |
| 2022-12-13 | LEA LEIV | 买入 (P) | Common Stock | 30,000 | USD 0.74 | USD 22,200 | SEC 申报 ↗ |
| 2022-09-28 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 25,000 | USD 0.76 | USD 19,000 | SEC 申报 ↗ |
| 2022-09-20 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 20,000 | USD 0.81 | USD 16,277 | SEC 申报 ↗ |
| 2022-06-27 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 5,000 | USD 1.00 | USD 5,000 | SEC 申报 ↗ |
| 2022-06-24 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 5,000 | USD 1.03 | USD 5,150 | SEC 申报 ↗ |
| 2022-06-06 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 890 | USD 1.01 | USD 899 | SEC 申报 ↗ |
Form 4 申报证据
16 transaction lines in the latest 365-day window; 56 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-11 | Moore David Scott | 买入 (P) | Common Stock | 21,700 | USD 11.53 | USD 250,201 | SEC 申报 ↗ |
| 2026-05-18 | MILLER RICHARD A MD | 买入 (P) | Common Stock | 6,932 | USD 12.04 | USD 83,453 | SEC 申报 ↗ |
| 2026-01-28 | Thompson Peter A. | 期权行权／转换 (M) | Common Stock | 210,000 | USD 5.33 | USD 1,119,450 | SEC 申报 ↗ |
展开近期 Form 4 证据 (3 grouped rows)
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CRVS |
| CIK | 0001626971 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 56 transaction lines from 2020-07-07 to 2026-06-11 30 P purchase lines · 8 S sale lines · 18 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.